U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07192471) titled 'A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma' on Aug. 12.
Brief Summary: The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Study Start Date: Jan. 23, 2026
Study Type: INTERVENTIONAL
Condition:
T-cell NHL (PTCL or CTCL)
Intervention:
DRUG: KK2223
Intravenous infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kyowa Kirin, Inc.
Published by HT Digital Content Services with permission from H...